KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Jazz Pharmaceuticals (JAZZ) Change in Intangibles (2018 - 2025)

Jazz Pharmaceuticals has reported Change in Intangibles over the past 9 years, most recently at $53.5 million for Q4 2025.

For Q4 2025, Change in Intangibles changed N/A year-over-year to $53.5 million; the TTM value through Dec 2025 reached $108.5 million, changed N/A, while the annual FY2025 figure was $108.5 million, N/A changed from the prior year.
Change in Intangibles for Q4 2025 was $53.5 million at Jazz Pharmaceuticals, up from $30.0 million in the prior quarter.
Over five years, Change in Intangibles peaked at $53.5 million in Q4 2025 and troughed at $17.9 million in Q3 2021.
A 3-year average of $30.3 million and a median of $25.0 million in 2022 define the central range for Change in Intangibles.